Cell-mediated immunity is an important component of immediate and long-term anti-viral protection. Dendritic cells (DCs) are essential for the induction of cell-mediated immunity by instructing the activation and differentiation of antigen-specific T cell responses. Activated DCs that express co-stimulatory molecules and pro-inflammatory cytokines are necessary to promote the development of type 1 immune responses required for viral control. Here we report that plant-derived virus-like particles (VLPs) bearing influenza hemagglutinins (HA) directly stimulate mouse and human DCs. DCs exposed to H1-and, to a lesser extent, H5-VLPs in vitro rapidly express co-stimulatory molecules and produce proinflammatory cytokines including IL-12, IL-6 and TNFa. Furthermore, these VLPs support the activation and differentiation of antigen-specific T cell responses. Mechanistically, H1-VLPs stimulate the activation of kinases typically activated downstream of pattern recognition receptors including AKT, p38, and p42/44 ERK. In vivo, immunization with plant-derived VLPs induce the accumulation of both cDC1s and cDC2 in the draining lymph node and a corresponding increase in T and B cells. VLPs devoid of HA protein activate DCs, suggesting they are intrinsically immunostimulatory. Together, the results demonstrate that these candidate plant-derived VLP vaccines have an inherent and direct stimulatory effect on DCs and can enhance the ability of DCs to promote Type 1 immune responses.
Introduction
Influenza viruses infect the human respiratory tract where they cause a spectrum of pathologies ranging from mild illness to lifethreatening disease [1] . Because these viruses mutate constantly in both humans and reservoir species, yearly vaccination remains the most effective method of prevention and containment [2] . Traditionally, hemagglutination-inhibition (HI) antibody response was used as a surrogate marker correlating with vaccine efficacy [3] . However, the cellular response (CD4 + and CD8 + T cells) can control infection in both animal models and humans [4] [5] [6] [7] and may be particularly important in elderly subjects who often mount weak or no antibody responses to standard, split virus vaccines [8, 9] . CD4 + T cells contribute to the control of viral infections by sustaining CD8 + T cell responses, supporting B cell functions and supporting long-term T and B cell memory [10, 11] . Cross-reactive CD4 + T cells that recognize conserved epitopes from the HA protein may therefore recognize drifted strains and participate in crossprotection [12] . Although the currently available vaccines have proved to be safe and to provide some degree of protection (i.e. efficacy averaging 40-60% in young healthy adult populations if vaccine matches circulating strain), it is increasingly clear that new vaccines capable of inducing broader and more durable immune responses (i.e. humoral, cellular, cross-reactive) are needed to improve vaccine efficacy [13, 14] . Virus-like particle (VLP) vaccines for influenza are selfassembling protein structures that contain viral antigens embedded in a lipid bilayer but lack any genetic material [15, 16] . Both pre-clinical (e.g. mouse, ferrets) and clinical studies have demonstrated that plant-derived VLP vaccine candidates bearing influenza hemagglutinin (HA) proteins can generate long-lived, crossreactive HA-specific humoral responses as well as poly-functional CD4 + T cell responses to both seasonal and avian strains [17] [18] [19] [20] .
The mechanisms by which these vaccines induce this broader immune response are not fully understood. Because dendritic cells stimulate and direct T cell immunity [21] and the activation of DCs is a necessary step in eliciting effective cellular responses against viruses, we examined whether these plant-derived VLPs had intrinsic immunostimulatory potential. We tested two VLP formulations; H1-VLP (Influenza A/California/04/09) and H5-VLP (A/ Indonesia/05/2005 strain) [16] with and without adjuvant. We observed that unadjuvanted H1-VLPs, and to a lesser extent H5-VLPs, stimulate both murine and human DCs to express costimulatory molecules and secrete pro-inflammatory cytokines including the T helper 1 (Th1) promoting cytokine IL-12. DCs stimulated with H1-VLP, and to a lesser extent H5-VLP, promoted the proliferation, differentiation and effector function of CD4 + T cells.
Exposure of murine DCs to H1-VLP also promoted crosspresentation of a simultaneously-administered model antigen ovalbumin (OVA) and CD8 + T cell effector differentiation. 
Materials & methods

Mice
Female wild-type C57BL/6 or BALB/c mice were purchased from Charles Rivers Laboratories at 6-8 weeks of age (Montreal, QC Canada). OTI and OTII transgenic mice were purchased from the Jackson Laboratory (Bar Harbor, ME USA) and bred in house. Animals were maintained in a specific pathogen-free environment. All experiments were conducted following the guidelines of the Canadian Council of Animal Care, as approved by the animal care committee of McGill University.
Production of influenza VLP vaccines
VLP vaccines were obtained from Medicago Inc. (Quebec City, QC) and produced as previously described [15, 17] . H1-VLPs contain HA from A/California/7/09 (H1N1) and H5-VLPs contain HA from A/ Indonesia/5/05 (H5N1). A detailed characterization of the morphology and biochemical content is reported here [15, 22] . In some experiments, 'empty' VLPs (eVLP) were used as an additional control. These nanoparticles are generated from plants transiently transfected with 'null' A. tumifasciens. They are approximately the same size as the HA-bearing VLPs and have very similar lipid composition (data not shown). However, since the influenza HA trimers drive budding of the VLPs, the down-stream processes used to isolate and purify the eVLPs are not identical to those used to generate the HA-VLPs.
Murine BMDC culture
Bone marrow was extracted from the femur and tibia of C57BL/6 or BALB/c mice. Briefly, bone marrow cells were differentiated to DCs in the presence of GM-CSF (20 ng/ml) in filtered complete DC media (cDCM: RPMI containing 10% FCS, 100 U/ml penicillin, 100 mg/ml of streptomycin, 50 mM b-Mercaptoethanol, 2 mM L-Glutamine (Wisent) and 1% non-essential amino acids) (Life Technologies/Thermofisher) on uncoated TC plates (Falcon) as described [23] . On day 8-10 of culture, immature DCs were harvested and stimulated in 96-well non-TC plates with either 10 ng/mL Escherichia coli LPS (serotype 0111:B4, Sigma), 5 mg/mL of H1-VLP, 5 mg/mL of H5-VLP (Medicago Inc, Ste Foy, QC: see above), 5 mg/ml of Alhydrogel (alum) (Brenntag/Cedarlane), VLPs with alum at 1:1 ratio, or 8.58 EU/mL of Agrobacterium-LPS (Agro-LPS) (List Biologicals Laboratories USA), 5 mg/ml OK432 (generously provided by Chugai Pharmaceuticals Co. INC., Japan) or as otherwise noted. After 18 h of incubation at 37°C, DCs were collected and analyzed by flow cytometry (FACS CANTOII, FORTESSA, Cell Vision Flow Cytometry Facility, McGill University).
Human monocyte-derived DC culture
After written informed consent, whole blood was obtained, peripheral blood mononuclear cells (PBMCs) were collected from the venous blood of healthy young adults (18-30 years old) at the MUHC Vaccine Study Center (Pierrefonds, QC). PBMCs were separated on a Ficoll density gradient and CD14 + monocytes were positively selected (Stem Cell Technologies, B.C. Canada), resuspended in cDCM and then plated in 6-well tissue culture plates (Falcon) at a concentration of 1 million cells/mL. Differentiation into moDCs was completed using human GM-CSF (100 ng/mL) and human IL-4 (50 ng/mL) (Peprotech). Human moDCs were fed with 1 ml of fresh media on day 3 and 6 of culture. On day 7, moDCs were harvested and activated with either 10 ng/ml LPS, 5 mg/mL of H1-VLP, 5 mg/mL of H5-VLP, 5 mg/mL of Alhydrogel (alum), VLPs with alum at 1:1 ratio, or 8.58 EU/mL of Agro-LPS. After 30 min of incubation at 37°C, moDCs were collected, protein expression was analyzed by Western. Otherwise, after 18 h of incubation at 37°C, moDCs were collected and analyzed by flow cytometry. These studies were approved by the Research Ethics Board of the McGill University Health Centre.
ELISA
Cell culture supernatants from DCs stimulated with LPS, VLPs or VLPs with alum, were collected after 18 h and quantified for IL12p70, IL-12p40, IL-6, IL-10, IL-1b and TNFa by enzyme-linked immunosorbent assay (ELISA) kits (eBioscience/Affymetrix) according to the manufacturer's instructions.
DC: T cell co-culture assays
On day 10 of culture, BMDCs from C57BL/6 mice were harvested and cultured for 6 h with whole ovalbumin (OVA) protein (in house) (0.001 mg, 0.01 mg or 0.1 mg per well) with either Agro-LPS (0.5 ng/mL), H1-VLP (3 mg/mL) or H5-VLP (3 mg/mL). T cells from OTII or OTI transgenic mice were isolated from the spleen and lymph nodes using CD4 + and CD8 + positive selection kits (Stem cell), respectively. Sorted T cells were then co-cultured with the activated DCs at a 1:10 ratio of DCs to T cells. Prior to co-culture, half of the isolated T cells were additionally stained with a violet proliferation dye (eBioscience/Affymetrix) to examine proliferation. On day 3-5, T cells were collected and analyzed by flow cytometry.
Flow cytometric analysis
Surface staining: Following activation, live DCs or T cells were stained with fluorochrome-conjugated antibodies and acquired on a FACSCANTO II or FACSFortessa flow cytometer (BD Pharmingen). Analysis was performed using FlowJo software (Tree Star, Oregon, USA). See figure legends for analysis gates. Intracellular staining: T cells were stimulated with 3 mg/mL Brefeldin A (eBioscience/Affymetrix), 0.5 mg/ml ionomycin (Sigma) and 0.05 mg/ml PMA (Sigma) for 4 h prior to their harvest. T cells were stained with fluorochrome-conjugated antibodies against surface markers, for 60 min at 4°C in the dark. T cells were then fixed and permeabilized with Foxp3 fix/perm buffer from eBioscience/Affymetrix for 40 min. Intracellular proteins were stained overnight at 4°C. See figure legends for analysis gates. All conjugated antibodies used in flow cytometry analyses were purchased from eBioscience/Affymetrix: Anti-human CD11c-Percp710 3.9; anti-human CD86-PeCy7 IT2.2; anti-human CD83-PE HB15e; anti-human CD14-FITC 61D3; anti-mouse CD11c-e450 N418; anti-mouse CD11c-APC-780N418; anti-mouse CD86-FITC GL1; anti-mouse CD86-PeCy7 GL1; anti-mouse CD40-APC 1C10; anti-mouse MHCII-AF700 M5/114.15.2; anti-mouse MHCII-APC-780 M5/114.15.2; antimouse MHCII-PE M5/114.5.2; anti-mouse Flt3 (CD135)-PE A2F10; anti-mouse CD115-AlexaFluor488 AFS98; anti-mouse CD62L-APC MEL-14; anti-mouse CD4-APC-780 RM4-5; anti-mouse CD4-e450 RM4-5; anti-mouse CD8-APC-780 53-6.7; anti-mouse CD8-e450 53-6.7; anti-mouse CD44-e450 IM7 anti-mouse CD44-PercpCy5.5 IM7; anti-mouse CD44-PeCy7 IM7; anti-mouse CD25-PE PC61.5; anti-mouse CD25-PeCy7 PC61.5; anti-mouse XCR1-BV650 ZET; anti-mouse CD3-FITC 17A2; anti-mouse CD3-Biotin 17A2; streptavidin V500 (BDHorizon 561419); anti-mouse B220-APC RA3-6B2; anti-mouse B220-FITC RA3-6B2; anti-mouse Ly6G-FITC 1A8; anti-mouse NK1.1-FITC PK136; anti-mouse CD69 FITC H1.2F3; anti-mouse CD172a-PeCy7 P84; anti-mouse T-bet-PeCy7 eBio4B10; anti-mouse IFNc-FITC XMG1.2; anti-mouse IFNc-APC XMG1.2; anti-mouse Granzyme B-FITC NGZB; anti-mouse IL-2-PE JES6-5H4; anti-mouse CD16/CD32 FcR Block 93; 7AAD Viability Staining Solution; Fixable Viability APC-780; Cell Proliferation dye efluor 450; 123count eBeads Counting Beads.
qRT-PCR
RNA from BMDCs was isolated using Trizol (Life Technologies, ThermoFisher), cDNA were synthesized using random primers and multiscribe reverse transcriptase (Applied Biosystems). Realtime qRT-PCR analysis was performed using SYBR green (FroggaBio). Relative expression of IL-12p40 and pro-IL-1b to HPRT was calculated using the 2-DDCt method. Real-time primers for HPRT, IL-12p40 and pro-IL-1b were designed by Primer3 and PrimerBlast. The primer sequences used are listed below: Hprt Fwd: CTC CGC CGG CTT CCT CCT CA Rev:ACC TGG TTC ATC ATC GCT AAT C IL12p40 Fwd: CTG GAG CAC TCC CCA TTC CT Rev: CGC CTT TGC ATT GGA CTT CG Il-1b Fwd: GCC ACC TTT TGA CAG TGA TGA G Rev:AAG GTC CAC GGG AAA GAC AC.
In vivo footpad injections
5 lg of VLPs, 0.1 lg of LPS, or PBS were injected into each footpad of female wild-type C57BL/6 mice at 6-8 weeks of age. After 24-36 h, the draining popliteal lymph nodes were digested and stained with antibodies for flow cytometry.
Statistics
Statistical analysis on murine data was performed using oneway ANOVA using GraphPad Prism. Statistical analysis on human data was performed using the Friedman test (nonparametric test). Single stars above bars indicate statistically significant difference relative to control. Lines indicate where direct comparisons were made between groups. Differences were considered significant at p < 0.05.
Results
To examine whether plant-derived VLPs bearing influenza HA proteins could directly activate DCs, BM-derived DCs from both C57BL/6 and BALB/c mouse strains were stimulated with H1-VLPs or H5-VLPs and examined for expression of co-stimulatory molecules and cytokine production. LPS from E. coli was used as a control in all experiments. DCs exposed to H1-VLPs increased the expression of co-stimulatory molecules CD86 and CD40, markers of proinflammatory DC activation which were further increased by alum ( Fig. 1A and B ). H5-VLPs were less stimulatory than H1-VLPs although their activity was also enhanced by alum (Fig. 1A  and B) . H1-VLPs induced the secretion of pro-inflammatory cytokines IL-12p40, IL-6, and TNFa and levels were enhanced with the addition of alum (Fig. 1C) . In contrast, pro-inflammatory cytokine secretion in response to H5-VLPs was generally weak and was not significantly enhanced by alum (Fig. 1C) . IL-10 secretion, which can be induced in murine DCs by LPS, also increased in response to H1-VLP stimulation, but not H5-VLPs. Increasing the concentration of H5-VLPs improved their immunostimulatory capacity, but cytokine levels were never comparable to those stimulated by H1-VLPs (Fig. S1 ). Together, these findings demonstrate that H1-containing VLPs, and to a lesser extent H5-VLPs, can directly stimulate murine DCs to acquire a pro-inflammatory phenotype.
Since these VLPs are produced in plants using a Gram-negative bacterial vector (Agrobacterium tumefaciens), small amounts of Agro-LPS are found in VLP preparations (range $312-1610 EU/ mL in Drug Substance). Thus, the possible effect of Agro-LPS on murine DC activation was evaluated. DCs from young mice were stimulated for 18 h with 1.72 ng/ml (8.58 EU/ml) of Agro-LPS (amount found in 5 mg/ml of H1-VLP) and the induction of activation marker expression and cytokine production was compared to 1.72 ng/ml of E. coli LPS (serotype 0111:B4). DCs stimulated with Agro-LPS alone expressed CD86 and CD40 levels almost identical to the unstimulated control (Fig. S2 ). The addition of alum with Agro-LPS did not increase CD86 or CD40 expression (data not shown).
We also examined whether the VLPs could similarly stimulate human DCs. Human monocyte-derived DCs (moDCs) were stimulated with either 5 mg/mL of H1-or H5-VLP for 18 h with or without alum. Following stimulation, the activation status was evaluated using CD83 and CD86 expression as well as cytokine secretion. We observed that both H1-and H5-VLPs significantly induced the expression of CD83 and CD86 compared to the negative control and expression was not increased by alum (Fig. 1D) . H1-VLP (with or without alum) significantly increased the secretion of IL-6, TNFa and IL-10 ( Fig. 1E) . Although there was a trend observed in some experiments for increased cytokine secretion with H5-VLP stimulation, significance was not reached as compared to the control cultures (Fig. 1E) . Neither alum nor Agro-LPS on their own induced up-regulation of activation marker expression (Fig. 1D ) and did not stimulate any significant cytokine secretion (Fig. 1E) . With respect to IL-6, IL-10, and TNFa production and CD83 expression, H1-VLPs were generally more stimulatory than H5-VLPs. However, differences between H1-and H5-VLPs were not observed for CD86 upregulation and IL-12 production.
The promotion of effective Type 1 immunity (including both Th1 CD4
+ and CD8 + cytotoxic T lymphocyte responses (CTL) is necessary for optimal protection from most viruses and is thus an important criterion for evaluating novel influenza vaccine candidates. Because the plant-derived HA-VLPs stimulated the production of Type 1 immunity promoting cytokines by both murine and human DCs (IL-12), we examined whether the VLPstimulated DCs could promote the development of Th1 responses.
DCs from C57BL/6 mice were exposed to H1-and H5-VLPs for 6 h in the presence of whole ovalbumin (OVA) and subsequently cocultured with OVA-specific TCR transgenic CD4 + T cells from OTII transgenic mice. CD4 + T cell responses were evaluated by flow cytometry based on the extent of proliferation, activation marker expression (CD44 and CD25), Th1 transcription factor (T-bet) up- regulation and effector cytokine secretion (IFNc). We observed that both H1-and H5-VLP-stimulated DCs promoted the activation (measured by CD44 expression) and proliferation of CD4 + T cells ( Fig. 2A and B) . Both H1-and H5-VLP-stimulated DCs promoted a significant increase in T-bet expression compared to OVAstimulated DCs, highlighting the promotion of a Th1 program (Fig. 2C) . Consistently, the percentage of activated CD4 + T cells producing IFNc (CD44 + IFNc + ) was also increased by H1-and H5-stimulated DCs, indicating that both VLPs can induce Th1 effector function (Fig. 2D) . Although the increase in Th1 differentiation by H5-stimulated DCs was routinely observed, statistical significance was not achieved in every experiment. Overall, the CD4 + T cell responses promoted by DCs exposed to H1-VLPs were stronger and more consistent than those observed following H5-VLP stimulation, similar to the differences observed in murine DC activation. VLPs are extracellular particles therefore antigen must be crosspresented on MHCI in order to stimulate antigen-specific CD8 + T cell responses. Thus, the ability of VLP-stimulated DCs to crosspresent antigen and stimulate CD8 + T cells was also evaluated.
DCs from C57BL/6 mice were stimulated for 6 h with H1-or H5-VLPs in the presence of OVA and subsequently co-cultured with OVA-specific TCR transgenic CD8 + T cells from OTI transgenic mice. ) was significantly increased with H1-, but not H5-stimulated DCs compared to OVA alone (Fig. 3A) . A trend for H1-and H5-VLP stimulated DCs to activate CD8 + T cells to produce IFNc (CD44 + IFNc + ) was also observed (Fig. 3A) . The expression of T-bet and granzyme B, as well as the percentage of activated CD8 + T cells producing T-bet and granzyme B, were significantly increased with H1-VLP-stimulated DCs compared to negative controls (Fig. 3B) . Again, the changes induced with H5-VLP-activated DCs trended in the same direction but did not reach significance compared to the OVA control (Fig. 3B) . Together, these findings suggest that H1-VLP, and to some extent H5-VLP, can stimulate DCs to cross-present antigen to CD8 + T cells and promote antigen-specific CD8 + T cell responses.
To begin to understand the mechanisms by which the plantderived VLPs mediate DC activation, we first determined whether they stimulate a priming signal (much like pattern recognition receptor ligation), or whether their particulate nature activated mechanisms associated with inflammasome activation. In murine, but not human DCs, IL-1b secretion is dependent on two signals; a priming signal that leads to Il1b gene transcription and then a second signal mediated by the inflammasome that results in IL-1b protein cleavage and secretion. We found that exposure of DCs to the H1-VLP increased both Il1b and Il12b transcription. (Fig. 4A) . Although H5-VLP stimulated significant transcription of pro-IL-1b compared to the control, the levels were similar to Agro-LPS and were less than H1-VLP (Fig. 4A) . However, VLPs on their own could not induce the secretion of active IL-1b and required the addition of alum, which stimulates inflammasome activation, for significant secretion of IL-1b (Fig. 4B ). Together these results indicate that the plant-derived VLPs, in particular H1-VLP, acts as signal 1 to prime the activation of DCs and that, as expected, alum then acts as signal 2 to trigger inflammasome assembly, resulting in pro-IL-1b cleavage. Human moDCs stimulated with H1-VLP or LPS were able to produce significant amounts of IL-1b in the absence of alum (Fig. 4C ). This result is consistent with previous reports that human monocytes have a path to IL-1b production distinct from mouse cells that does not require a second signal [24] [25] [26] . Since H1-VLP was shown to act as a strong priming signal for DC activation, we determined which intracellular signaling pathways H1-VLP might activate to induce the expression of inflammatory cytokines and co-stimulatory molecules. DCs were exposed to H1-or H5-VLPs and the activation of signaling pathways known to be important for DC activation were examined. As expected, LPS strongly activated many kinases known to be downstream of PRRs (Fig. 4D) . In DCs, H1-VLP induced the phosphorylation and thus activation of AKT, p42/44 and p38, but only minimally activated JNK (Fig. 4D) . H5-VLP induced activation of AKT, p38 and to a lesser extent p42/44 but all were less strongly induced than with H1-VLP exposure. Similar results were obtained from human monocyte-derived DCs (Fig. 4E) . Together, these results demonstrate that H1-VLP, and to a lesser extent H5-VLPs, directly activate kinase cascades that lead to the activation of DCs with their production of pro-inflammatory cytokines and ability to stimulate T cell responses.
To determine whether H1 and H5-VLPs stimulated DCs in vivo, the footpads of mice were injected with H1-VLP or H5-VLP. Injection of the VLPs led to a trend for increased numbers of total DCs, conventional DC1s (cDC1s; XCR1 + ) and cDC2s (CD172a + ) in the draining lymph nodes 36 h following immunization (Fig. 5A) . Con- sistent with DC activation and lymphocyte recruitment, we found a significant increase in the total number of B cells and T cells (Fig. 5B) , some of which expressed markers of activation (CD69 + and CD44 + respectively). These experiments demonstrate that H1-and H5-containing VLPs have inherent immunostimulatory activity in vivo. Influenza HA proteins are not thought to have any intrinsic immunostimulatory properties on their own. Therefore, we assessed the ability of the VLPs devoid of HA proteins to stimulate murine and human DCs. Biochemical analyses of the VLPs reveal the presence of low levels of residual host cell proteins and glucosylceramides associated with plant lipid rafts [15] . Empty VLPs (eVLP), the VLP without the HA proteins, stimulated costimulatory molecule expression and cytokine production by DCs (Figs. 6A, B and S3 ). LPS and OK432 bacterial vaccine were used as controls. DCs stimulated with eVLPs also induced in vitro T cell responses (Fig. 6C) , demonstrating enhanced function of the stimulated DCs. As in Fig. 5 , eVLPs were injected into the footpads of A) The mRNA levels of Il-1b and Il-12p40 were measured by qRT-PCR after DCs were activated for 6 h with 5 mg/ml of H1-or H5-VLPs, with or without 5 mg/ml of alum, compared to Agro-LPS (8.58 EU/ml) and LPS (10 ng/ml). B) The secretion of active IL-1b by DCs in response to VLP and alum stimulation was measured by ELISA. Data from (A) and (B) are shown as mean ± SD. and are representative of three independent experiments. (C) IL-1b secretion by human moDCs from 14 adult donors (18-30 years old). Each dot represents one donor and data are shown as mean ± SEM. Mouse (D) and human (E) DCs were activated for the indicated times with 10 ng/ml of LPS, 5 mg/ml of H1-VLP or 5 mg/ml of H5-VLP. Western blot results show the phosphorylation (p) of: AKT, JNK, p42/44 (ERK1/2), and p38. Tubulin (D) or b-actin (E) was used as a loading control. Results are from one experiment and representative of three independent experiments. mice and compared to PBS controls. eVLPs induced substantial DC accumulation in the draining LN indicating that the eVLPs were stimulatory in vivo. The proportion of cDC subsets were not significantly different upon eVLP immunization, with an increase in both cDC1s and cDC2s (Fig. 6D) . To determine whether eVLPs also stimulate human DCs, moDCs were stimulated with eVLP. eVLPs induced the activation of p38 and p44/42 but minimal activation of AKT (Fig. 6E ).
Discussion
High serum antibody titers can protect against many viral infections, including influenza. Although antibodies that mediate hemagglutination inhibition (HI) have long been used as surrogates to license influenza vaccines [3] , there is increasing interest in formulations that can induce more effective and broader immunity. Plant-derived VLP vaccines bearing the influenza virus HA protein have recently been shown to generate broad and crossreactive cellular and humoral immune responses in both animal models [16] and clinical trials [17] . In animal challenge studies with highly pathogenic avian strains, some of the VLP-vaccinated animals are protected despite very low or even undetectable antibody titers [16, 18] . To better understand the mechanism(s) that underlie the broader pattern of immunity induced by the plantderived vaccines, we evaluated the innate stimulatory potential of H1-and H5-containing VLPs and eVLPs devoid of any HA protein, in DCs isolated from mice and humans. We found that the plant-derived VLPs can directly activate DCs and stimulate subsequent CD4
+ and CD8 + T cell responses. In vitro, H1-VLPs were gen- Overall, these animal data are consistent with early studies of T cell responses in humans with the same H1-and H5-VLPs, in which strong CD4
+ and more limited CD8 + T cell responses to the H1 antigen were detectable up to 6 months after H1-VLP vaccination while only CD4 + T cell responses were seen in the H5-VLP vaccine recipients [17] . Furthermore, the H5-VLP vaccine candidate needed to be adjuvanted in order to see significant CD4 + T cell responses, while the H1-VLP vaccine did not [17] . Although our mouse data suggest that H1-and H5-VLPs that differ in only their HA cargo have different capacity to stimulate DCs, the differences in apparent T cell immunogenicity of these two formulations in humans may be attributable, at least in part, to prior experience of most human study subjects with H1 but not H5 antigens. However, prior exposure would not affect the studies reported here. Although our principal interest was in the intrinsic stimulatory capacity of the plant-derived VLPs, alum was included in many of our experiments because of its widespread use. Alum remains the most commonly used adjuvant in human vaccines, even though aluminum-containing adjuvants have long been thought of as promoting Th2 responses [27, 28] . In pre-clinical studies (ferret) and early clinical trials with the plant-derived VLP vaccines, alum had shown unexpected promise in eliciting T cell responses and protection from challenge [17, 29] . In the current work, we focused on testing the combined effects of alum and VLPs on DC activation. Similar to previous findings [30, 31] , we observed that alum by itself does not activate murine or human DCs to any significant degree. However, when alum was combined with H1-VLP, there was a marked increase in activation marker expression and cytokine secretion from murine DCs compared to H1-VLP alone. Alum was less effective at promoting enhanced responses to H5-VLPs. In combination with H1-VLPs, alum drove increased secretion of Th1-promoting cytokines such as IL-12p70 and IL-12p40. This finding suggests an unexpected feature of combined VLP plus alum stimulation and demonstrates that alum can play a role in promoting Th1 responses in certain contexts. Because particles are known to activate the inflammasome, a known target of alum [32] , we examined whether the VLPs had any impact on inflammasome activation. Although IL-1b secretion by DCs was only detected when H1-VLP and alum were used together, Il1b transcription occurred following exposure of DCs to H1-VLP alone. These findings suggest that the plant-derived VLPs serve as a priming rather than an activating signal for the inflammasome. When primed by the plantderived VLP, alum can then support greater Th1 responses. This observation raises the possibility that aluminum-containing adjuvants, in some circumstances, may stimulate immune responses beyond promoting antibody production.
In in vitro assays used to evaluate the innate immunestimulatory potential of H1-and H5-VLPs on murine DCs, we found that H1-VLPs were more stimulatory than H5-VLPs. For human cells, even though there were fewer differences in the ability of H1-VLPs and H5-VLPs to activate DCs, H1-VLPs still stimulated greater cytokine production. Interestingly, in vivo, the ability of H1-and H5-VLPs to stimulate in vivo the recruitment of DCs, B cells, and T cells to the draining lymph node was equivalent. The observations that the H5-VLP effectively elicits an immune response in vivo are in accordance with the findings obtained during clinical trials [17] . Considering that both these VLPs are produced using the same expression platform, it was unexpected to observe such a striking difference between their innate stimulatory capacities. Detailed morphological analyses of H1-and H5-containing VLPs by cryostatic electron microscopy did not reveal differences between the two types of VLPs [22] . Even when much higher doses of H5-VLPs were used to stimulate murine DCs, the expression of activation markers never reached the same level as with H1-VLP in vitro. These differences were also evident in the activation of signaling pathways that are essential for the development of a pro-inflammatory phenotype capable of promoting Type 1 immune responses. Interestingly DCs activated by eVLPs resemble those activated by H1-VLPs. Further work is needed to determine the mechanism behind the differential activation of DCs by empty VLPs, H1 and H5-containing VLPs. Such intrinsic stimulatory capacity could be the result of the non-HA components of the VLPs (ie: plant-origin lipids/glycolipids) or to the physical structure of the VLPs themselves. We also cannot definitively rule out a role for residual Agrobacterium-or plant-derived proteins, particularly in response to eVLP. Although >98.5% of the protein in the VLP vaccine is viral HA, the eVLPs cannot be produced in the same way and have slightly higher residual protein content. None of the proteins identified to date in either the VLP vaccine or the eVLPs is known to have immunostimulatory activity. Recent work suggests that the initial interactions of plant-derived VLPs with antigen presenting cells recapitulate those of intact virions [33] . However, the different binding specificities of the hemagglutinin trimers themselves (a2,6 and a2,3 sialic acid respectively) may result in distinct VLP interactions with immune cells [34] .
Injection in vivo of eVLPs, H1-and H5-VLPs resulted in an increase in cDC1 and cDC2 populations in the draining lymph node. Both cDC1s and cDC2s are capable of stimulating antigen-specific CD4 + T cell responses. While XCR1 + cDC1s are more widely known to be able to cross-present antigen and stimulate CD8 + T cells, cDC2s
can also stimulate cross-presentation in some contexts, in particular for human DCs [35] . These findings suggest that plant-derived VLPs may stimulate the activation of multiple DC types to induce protective immunity. Future studies will assess the contribution of cDC1s and cDC2s to the induction of CD4 + and CD8 + T cell immune responses in vivo and the generation of protective immunity. In this study, we demonstrate the intrinsic stimulatory potential of plant-derived VLPs. These VLP vaccine candidates effectively activate murine and human DCs in vitro. The combination of alum and plant-derived VLPs had the unexpected effect of enhancing the production of Th1-promoting cytokines by DCs. The cooperation between alum and plant-derived VLPs raises the possibility that this well-established adjuvant could be re-purposed to drive broader immune responses in certain circumstances. Overall, the unusual innate stimulatory activities of the plant-derived VLPs may prove to be useful in generating more effective vaccines for influenza as well as other targets for which both humoral and cellular responses are important. 
